Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NPD's Cash to Debt is ranked higher than
100% of the 626 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.55 vs. NPD: No Debt )
NPD' s 10-Year Cash to Debt Range
Min: 2.27   Max: No Debt
Current: No Debt

Equity to Asset 0.55
NPD's Equity to Asset is ranked higher than
84% of the 607 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. NPD: 0.55 )
NPD' s 10-Year Equity to Asset Range
Min: 0   Max: 0.86
Current: 0.55

0
0.86
Interest Coverage No Debt
NPD's Interest Coverage is ranked higher than
95% of the 429 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 17.29 vs. NPD: No Debt )
NPD' s 10-Year Interest Coverage Range
Min: 17.73   Max: 9999.99
Current: No Debt

17.73
9999.99
F-Score: 4
Z-Score: 3.73
M-Score: -2.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -0.10
NPD's Operating margin (%) is ranked higher than
53% of the 628 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.46 vs. NPD: -0.10 )
NPD' s 10-Year Operating margin (%) Range
Min: -2.92   Max: 9.25
Current: -0.1

-2.92
9.25
Net-margin (%) -0.47
NPD's Net-margin (%) is ranked higher than
54% of the 628 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.03 vs. NPD: -0.47 )
NPD' s 10-Year Net-margin (%) Range
Min: -2.75   Max: 8.04
Current: -0.47

-2.75
8.04
ROE (%) -1.67
NPD's ROE (%) is ranked higher than
54% of the 614 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.17 vs. NPD: -1.67 )
NPD' s 10-Year ROE (%) Range
Min: -5174.35   Max: 10.04
Current: -1.67

-5174.35
10.04
ROA (%) -0.89
NPD's ROA (%) is ranked higher than
54% of the 629 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.13 vs. NPD: -0.89 )
NPD' s 10-Year ROA (%) Range
Min: -19.18   Max: 7.3
Current: -0.89

-19.18
7.3
ROC (Joel Greenblatt) (%) -0.72
NPD's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 628 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.05 vs. NPD: -0.72 )
NPD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -20.69   Max: 115.25
Current: -0.72

-20.69
115.25
Revenue Growth (3Y)(%) 8.30
NPD's Revenue Growth (3Y)(%) is ranked higher than
84% of the 535 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.80 vs. NPD: 8.30 )
NPD' s 10-Year Revenue Growth (3Y)(%) Range
Min: -11.4   Max: 58.6
Current: 8.3

-11.4
58.6
EBITDA Growth (3Y)(%) -31.90
NPD's EBITDA Growth (3Y)(%) is ranked higher than
52% of the 488 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.20 vs. NPD: -31.90 )
NPD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 122.4
Current: -31.9

0
122.4
» NPD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

NPD Guru Trades in Q2 2014

Jim Simons 560,600 sh (-11.68%)
» More
Q3 2014

NPD Guru Trades in Q3 2014

Jim Simons 588,200 sh (+4.92%)
» More
Q4 2014

NPD Guru Trades in Q4 2014

Jim Simons 639,422 sh (+8.71%)
» More
Q1 2015

NPD Guru Trades in Q1 2015

Jim Simons 651,500 sh (+1.89%)
» More
» Details

Insider Trades

Latest Guru Trades with NPD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 15.67
NPD's Forward P/E is ranked higher than
83% of the 689 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 25.13 vs. NPD: 15.67 )
N/A
P/B 1.70
NPD's P/B is ranked higher than
75% of the 689 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.63 vs. NPD: 1.70 )
NPD' s 10-Year P/B Range
Min: 0.69   Max: 4.86
Current: 1.7

0.69
4.86
P/S 0.50
NPD's P/S is ranked higher than
72% of the 689 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.61 vs. NPD: 0.50 )
NPD' s 10-Year P/S Range
Min: 0.29   Max: 6.71
Current: 0.5

0.29
6.71
POCF 231.00
NPD's POCF is ranked higher than
59% of the 689 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.68 vs. NPD: 231.00 )
NPD' s 10-Year POCF Range
Min: 6.73   Max: 745
Current: 231

6.73
745
EV-to-EBIT -36.41
NPD's EV-to-EBIT is ranked lower than
51% of the 689 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.64 vs. NPD: -36.41 )
NPD' s 10-Year EV-to-EBIT Range
Min: -1481   Max: 144.2
Current: -36.41

-1481
144.2
Shiller P/E 35.20
NPD's Shiller P/E is ranked higher than
75% of the 689 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 39.69 vs. NPD: 35.20 )
NPD' s 10-Year Shiller P/E Range
Min: 10.13   Max: 45.43
Current: 35.2

10.13
45.43
Current Ratio 2.05
NPD's Current Ratio is ranked higher than
90% of the 610 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.14 vs. NPD: 2.05 )
NPD' s 10-Year Current Ratio Range
Min: 0.91   Max: 6.94
Current: 2.05

0.91
6.94
Quick Ratio 1.16
NPD's Quick Ratio is ranked higher than
86% of the 610 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.66 vs. NPD: 1.16 )
NPD' s 10-Year Quick Ratio Range
Min: 0.31   Max: 6.33
Current: 1.16

0.31
6.33
Days Inventory 118.77
NPD's Days Inventory is ranked higher than
54% of the 689 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 42.56 vs. NPD: 118.77 )
NPD' s 10-Year Days Inventory Range
Min: 44.74   Max: 122.17
Current: 118.77

44.74
122.17
Days Sales Outstanding 16.86
NPD's Days Sales Outstanding is ranked higher than
76% of the 689 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.48 vs. NPD: 16.86 )
NPD' s 10-Year Days Sales Outstanding Range
Min: 6.04   Max: 17.85
Current: 16.86

6.04
17.85

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 13.80
NPD's Dividend Yield is ranked higher than
99% of the 522 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.87 vs. NPD: 13.80 )
NPD' s 10-Year Dividend Yield Range
Min: 0.85   Max: 21.85
Current: 13.8

0.85
21.85
Yield on cost (5-Year) 13.80
NPD's Yield on cost (5-Year) is ranked higher than
99% of the 525 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.03 vs. NPD: 13.80 )
NPD' s 10-Year Yield on cost (5-Year) Range
Min: 0.85   Max: 21.85
Current: 13.8

0.85
21.85
Share Buyback Rate 1.50
NPD's Share Buyback Rate is ranked higher than
90% of the 408 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.30 vs. NPD: 1.50 )
NPD' s 10-Year Share Buyback Rate Range
Min: 4.6   Max: -27.1
Current: 1.5

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 1.80
NPD's Price/Tangible Book is ranked higher than
80% of the 689 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.80 vs. NPD: 1.80 )
NPD' s 10-Year Price/Tangible Book Range
Min: 0.96   Max: 4.66
Current: 1.8

0.96
4.66
Price/DCF (Projected) 1.50
NPD's Price/DCF (Projected) is ranked higher than
84% of the 689 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.60 vs. NPD: 1.50 )
NPD' s 10-Year Price/DCF (Projected) Range
Min: 0.68   Max: 7.98
Current: 1.5

0.68
7.98
Price/Median PS Value 0.50
NPD's Price/Median PS Value is ranked higher than
96% of the 689 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.30 vs. NPD: 0.50 )
NPD' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 6.68
Current: 0.5

0.39
6.68
Earnings Yield (Greenblatt) -2.70
NPD's Earnings Yield (Greenblatt) is ranked lower than
52% of the 623 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.80 vs. NPD: -2.70 )
NPD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.7   Max: 153.9
Current: -2.7

-2.7
153.9
Forward Rate of Return (Yacktman) -21.77
NPD's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 453 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.69 vs. NPD: -21.77 )
NPD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -50.1   Max: 1.1
Current: -21.77

-50.1
1.1

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:WAG, RAD, PETS, DSCM, CVS, PERF » details
Traded in other countries:4CSA.Germany,
China Nepstar Chain Drugstore Ltd was incorporated in the Cayman Islands in August 2004. The Company operates retail drugstore business. The Company provides professional and convenient pharmacy services and other merchandise, including over-the-counter drugs, nutritional supplements, herbal products, personal care products, family care products, as well as convenience products including consumable, seasonal and promotional items. It also offers private label products. The Company offers 523 nutritional supplements, including a variety of healthcare supplements, vitamins, minerals and dietary products. Its other products include personal care products such as skin care, hair care and beauty products, family care products such as portable medical devices for family use, birth control and early pregnancy test products, and convenience products, including soft drinks, packaged snacks, cleaning agents and stationery. The other products also include seasonal and promotional items tailored to local consumer demand for convenience and quality. The Company also provides ancillary services such as providing free blood pressure measurements in its stores. The Company competes with other retail drugstore chains or independent drugstores. As a distributor and retailer of pharmaceutical products, the Company is subject to regulation and oversight by different levels of the food and drug administration in China, in particular, the State Food and Drug Administration, or the SFDA.
» More Articles for NPD

Headlines

Articles On GuruFocus.com
High Yield George Soros Stocks: China Nepstar ADS, Chimera Investment, PDL BioPharma, MFA Mortgage I Apr 22 2010 
BURTON463 note on NPD Mar 11 2010 
BURTON463 note on NPD Mar 11 2010 
BURTON463 note on NPD Mar 11 2010 
China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results Aug 24 2009 
China Nepstar Chain Drugstore Announces Special Dividend Aug 24 2009 
Ron Baron Likes Layne Christensen, Ritchie Brothers Auctioneers, Bankrate and China Nepstar Mar 25 2008 

More From Other Websites
3:05 am China Nepstar Chain Drugstore CEO resigns for personal reasons May 25 2015
China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment May 22 2015
China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment May 22 2015
China Nepstar Chain Drugstore to Report First Quarter 2015 Financial Results on May 26, 2015 May 08 2015
China Nepstar Chain Drugstore to Report First Quarter 2015 Financial Results on May 26, 2015 May 08 2015
CHINA NEPSTAR CHAIN DRUGSTORE LTD. Financials Apr 28 2015
China Nepstar Chain Drugstore Filed 2014 Annual Report on Form 20-F Apr 24 2015
China Nepstar Chain Drugstore Filed 2014 Annual Report on Form 20-F Apr 24 2015
Rite Aid (RAD) Appoints Rempel to Enhance IT Solutions - Analyst Blog Apr 21 2015
Will China Nepstar Chain Drugstore (NPD) Continue to Surge Higher? - Tale of the Tape Apr 10 2015
Rite Aid (RAD) Tops Q4 Earnings and Sales, Guides FY16 - Analyst Blog Apr 09 2015
China Nepstar Chain Drugstore Ltd Earnings Call scheduled for 8:00 am ET today Mar 30 2015
Q4 2014 China Nepstar Chain Drugstore Ltd Earnings Release - Before Market Open Mar 30 2015
China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results Mar 30 2015
China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2014 Financial Results Mar 30 2015
China Nepstar Chain Drugstore to Report Fourth Quarter and Fiscal Year 2014 Financial Results on... Mar 03 2015
China Nepstar Chain Drugstore to Report Fourth Quarter and Fiscal Year 2014 Financial Results on... Mar 03 2015
Nepstar: Activist Investor Makes "Urgent Appeal" For Change Mar 02 2015
China to allow online sales of prescription drugs as early as this month - sources Jan 09 2015
Mid-Day Gainers From December 30: Neuroderm, Neonode And More Dec 30 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK